Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL4819764

Cc1cc(C)c2oc(-c3ccc(-c4nn(C5CCC(N6CCN(C)CC6)CC5)c5ncnc(N)c45)cc3F)nc2c1.N

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 15/20 0.76
IGF1R P08069 15/20 0.76
ERBB4 Q15303 15/20 0.76
ERBB2 P04626 14/20 0.76
ERBB3 P21860 14/20 0.76
LCK P06239 5/20 0.51
SRC P12931 5/20 0.51
TEK Q02763 4/20 0.51
KDR P35968 3/20 0.51
BTK Q06187 2/20 0.51
AURKB Q96GD4 2/20 0.51
PLK4 O00444 1/20 0.51
MAPK13 O15264 1/20 0.51
PDPK1 O15530 1/20 0.51
DAPK3 O43293 1/20 0.51
JAK2 O60674 1/20 0.51
ROCK2 O75116 1/20 0.51
RPS6KA5 O75582 1/20 0.51
MAP4K4 O95819 1/20 0.51
PAK4 O96013 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL4826484 0.86 EGFR (0.67) EGFRIGF1RERBB4ERBB2ERBB3
SCHEMBL6430800 0.86 EGFR (1.00) EGFRIGF1RERBB4ERBB2ERBB3
SCHEMBL4819751 0.86 EGFR (1.00) EGFRIGF1RERBB4ERBB2ERBB3
SCHEMBL6430835 0.82 EGFR (0.86) EGFRIGF1RERBB4ERBB2ERBB3
SCHEMBL6430837 0.82 EGFR (0.86) EGFRIGF1RERBB4ERBB2ERBB3
Ammonia Solution, Strong SCHEMBL4826337 0.80 EGFR (0.57) EGFRIGF1RERBB4ERBB2ERBB3
SCHEMBL5803264 0.79 SRC (0.67) EGFRIGF1RERBB4ERBB2ERBB3
SCHEMBL5804408 0.79 SRC (0.67) EGFRIGF1RERBB4ERBB2ERBB3
SCHEMBL5801690 0.79 SRC (0.67) EGFRIGF1RERBB4ERBB2ERBB3
SCHEMBL5804409 0.79 SRC (0.67) EGFRIGF1RERBB4ERBB2ERBB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332497-B2 As inhibitors of protein kinases ABBOTT GMBH & CO KG (DE) 2008-02-19 US disclosed
US-20040006083-A1 Pyrazolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006083-A1 Pyrazolopyrimidines as therapeutic agents DPYD, UGT1A1, ABCB1 EGFR 1992/4885IGF1R 1680/4885ERBB4 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.